Granted New U.S. Composition of Matter Patent for ATH434
Filed with ASX · · 5 pages · English
Alterity Therapeutics Ltd. on 6ix
Story so far
Earlier from Alterity Therapeutics
- Application for quotation of securities - ATH
- Alterity to Present at Canaccord Genuity Growth Conference
- Alterity Therapeutics Releases Appendix 4C – Q4 FY26 Quarterly Cash Flow Report & Corporate Update
- Quarterly Activities/Appendix 4C Cash Flow Report
- Upcoming Expiry of ATHO Listed Options
Later from Alterity Therapeutics
- Alterity Therapeutics Announces Granting of New U.S. Composition of Matter Patent for ATH434
- Disclosure Under Takeovers Panel GN 20
- Appendix 4G
- Corporate Governance Statement
- Appendix 4E and 2026 Annual Report
Follow Alterity Therapeutics into a list and get an email when it puts out news.
Follow Alterity Therapeutics